The U.S. Food and Drug Administration (FDA) has accepted a new drug application for gedatolisib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA ...
Priority Review granted for CUTX-101 could expedite its path to market, potentially becoming the first FDA-approved treatment for Menkes disease. Cyprium is eligible to receive up to $129 million in ...
Financial applications, ranging from mobile banking apps to payment gateways, are among the most targeted systems worldwide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results